Benzinga · Mar 4, 2026
PL
NASDAQ · PLSE
Pulse Biosciences, Inc.
Healthcare · Medical - Instruments & Supplies
$52.24
Down-$3.24 (-5.84%)
Updated Oct 31, 2026, 2:39 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 933.16M
- P/E ratio
- -13.62
- Dividend yield
- 0.00%
- 52-week range
- $12.56 – $58.90
- Volume
- 466.45K
- Avg. volume
- 185.65K
Price performance · PLSE
PLSE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PLSE closed at $52.24 after 21 trading sessions, up 9.06% for the selected period.
- Last close
- $52.24
- Period change
- +9.06%
- Period low
- $44.43
- Period high
- $55.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $54.33 | $54.87 | $51.39 | $52.24 | 466.45K |
| Oct 29, 2026 | $53.74 | $56.51 | $53.74 | $55.48 | 344.68K |
| Oct 28, 2026 | $53.12 | $54.725 | $52.76 | $53.67 | 280K |
| Oct 27, 2026 | $53.42 | $53.77 | $52.46 | $53.20 | 328.96K |
| Oct 26, 2026 | $52.75 | $53.60 | $52.071 | $52.66 | 282.62K |
| Oct 23, 2026 | $52.44 | $55.00 | $51.47 | $53.02 | 453.02K |
| Oct 22, 2026 | $50.92 | $53.67 | $50.00 | $52.68 | 421.42K |
| Oct 21, 2026 | $51.16 | $52.03 | $50.067 | $51.31 | 317.92K |
| Oct 20, 2026 | $47.25 | $52.325 | $47.25 | $50.84 | 385.98K |
| Oct 19, 2026 | $44.58 | $48.12 | $44.58 | $47.55 | 342.45K |
| Oct 16, 2026 | $45.49 | $46.67 | $43.32 | $44.43 | 327.43K |
| Oct 15, 2026 | $45.13 | $46.67 | $43.96 | $45.59 | 425.63K |
| Oct 14, 2026 | $47.60 | $48.9708 | $44.80 | $46.32 | 440.3K |
| Oct 13, 2026 | $53.02 | $53.21 | $48.01 | $48.54 | 455.47K |
| Oct 12, 2026 | $53.53 | $53.98 | $50.15 | $52.45 | 434.41K |
| Oct 9, 2026 | $49.98 | $53.97 | $49.98 | $53.81 | 367.6K |
| Oct 8, 2026 | $48.90 | $50.32 | $47.31 | $49.98 | 315.59K |
| Oct 7, 2026 | $49.11 | $49.93 | $48.13 | $49.09 | 409.47K |
| Oct 6, 2026 | $51.26 | $51.26 | $48.62 | $49.75 | 421.37K |
| Oct 5, 2026 | $47.89 | $50.99 | $47.47 | $50.50 | 433.45K |
| Oct 2, 2026 | $50.13 | $50.7122 | $47.7532 | $47.90 | 519.27K |
Latest PLSE news
The latest Smart Investors Daily articles mentioning PLSE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PLSE research
Overview
Company profile and research snapshot.
Company profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Oppenheimer | Outperform | — |
| Oct 6, 2026 | Canaccord Genuity | Buy | — |
| Sep 23, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | Freedom Capital Markets | Buy | — |
| Aug 17, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
ChartMill · Feb 19, 2026
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates
Pulse Biosciences narrows Q4 losses and beats revenue estimates, advancing key clinical trials for its bioelectric cardiac ablation technology.
Benzinga · Feb 19, 2026
Pulse Biosciences May Offer Up To $59.976M Common Shares
SEC.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
